Clinical Trials Logo

Pancreatic Carcinoma clinical trials

View clinical trials related to Pancreatic Carcinoma.

Filter by:

NCT ID: NCT01262040 Completed - Lung Cancer Clinical Trials

Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive

Start date: December 14, 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether narrowband imaging (NBI) makes it easier for a surgeon to see cancer. NBI is a kind of light. Normally, white light is used during surgery. White light uses many wavelengths of light. NBI only uses two wavelengths which highlight the blood vessels. This makes it easier for the surgeon to see blood vessels. Tumors often have more blood vessels than normal tissue. As a result, NBI may make it easier for the surgeon to see small tumors. In this study the surgeon will look with both normal white light and NBI. This way a comparison can be made to determine which is superior. Improved identification of tumors allows doctors and patients to make informed decisions about whether treatment is needed after surgery. It also provides additional information to determine which treatments may be best.

NCT ID: NCT00892736 Completed - Breast Carcinoma Clinical Trials

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Start date: April 20, 2009
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that do not respond to previous therapy. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00423254 Completed - Gastric Cancer Clinical Trials

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Start date: February 2007
Phase: Phase 1
Study type: Interventional

The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.